Sanofi's Lantus Solostar insulin pen faces supply challenges, patients struggle to find product
read at STAT ↗Negative
Sanofi's Lantus Solostar pen, a long-acting insulin glargine product, has become hard to locate in pharmacies.
The company says demand has risen due to broader market dynamics, and while the FDA has not declared an official shortage, patients report needing to call multiple stores.
Sanofi says it is accelerating production and expediting replenishment stock to restore availability.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Popular insulin product enters shortage as other pens leave market”
read at STAT ↗448 words · retrieved Jul 23
comments(0)
5-min edit window · permanent after that